Clinical trials: Ocular Inflammation
Atopic Keratoconjunctivitis
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC.
- Trial name
- NCT07395232
- Testing
- DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
- Where
- 19 sites in United States, Italy and 1 more
- Volunteers
- 153 people
- Sponsor
- Dompé Farmaceutici S.p.A
Pain, Inflammation
Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery
The primary objective of this study is to investigate the efficacy and safety of bromfenac ophthalmic solution for treatment of ocular inflammation and pain in subjects who undergo cataract extraction and intraocular lens…
- Trial name
- NCT00333918
- Testing
- bromfenac ophthalmic solution
- Where
- United States
- Volunteers
- 522 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Inflammation
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
This study is designed to assess how KPI-121 1% compares to prednisolone acetate in reducing inflammation after cataract surgery in young children.
- Trial name
- NCT03596723
- Testing
- KPI-121 1%, Prednisolone acetate
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Ocular Inflammation, Cataract
Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification
The purpose of this study is to evaluate the efficacy of Saturno II association on the control of ocular inflammation post-phacoemulsification
- Trial name
- NCT03580473
- Testing
- SATURNO II association, Vigadexa®
- Where
- Brazil
- Volunteers
- 118 people
- Sponsor
- EMS
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Cataract
A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%
This is a post-approval, open-label, randomized, self-controlled prospective clinical study to evaluate the safety and ocular efficacy of Dexycu in controlling postoperative ocular pain and inflammation associated with cataract…
- Trial name
- NCT04273282
- Testing
- Dexycu intracameral dexamethasone, Prednisolone Acetate
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Research Insight LLC
Corneal Endothelial Cell Loss, Ocular Pain
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery.
- Conditions
- Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
- Trial name
- NCT02128113
- Testing
- Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
- Where
- 15 sites in United States
- Volunteers
- 307 people
- Sponsor
- Biogen
Cataract
Nepafenac 0.3% Two Study
The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
- Trial name
- NCT01318499
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle 0.3%
- Where
- United States
- Volunteers
- 1,342 people
- Sponsor
- Alcon Research
Macular Edema Secondary to Inflammation
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
- Trial name
- PEAK (NCT06990399)
- Testing
- KSI-101
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- Kodiak Sciences Inc
Pterygia
Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia
To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.
- Trial name
- NCT00383396
- Testing
- Topical Cyclosporine
- Where
- United States
- Sponsor
- Innovative Medical
Uveitis
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
This study aims at evaluating real life effectiveness of originator adalimumab (Humira®) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including…
- Trial name
- HOPE (NCT03155243)
- Where
- 28 sites in Austria, Colombia and 10 more
- Volunteers
- 155 people
- Sponsor
- AbbVie
Ocular Infections, Irritations and Inflammations
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
- Trial name
- Hawaii-1 (NCT02163824)
- Testing
- KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%
- Where
- 23 sites in United States
- Volunteers
- 380 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Inflammation, Uveitis
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
Investigate the impact of the Fluocinolone Acetonide (FA) intravitreal implants
- Trial name
- NCT01060787
- Testing
- Fluocinolone Acetonide 0.59 mg, Fluocinolone Acetonide 2.1 mg
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Bausch & Lomb Incorporated
Cataract
Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension (manufactured by Indoco remedies Ltd.
- Trial name
- NCT03499873
- Testing
- Nepafenac 0.3% Oph Susp, Nepafenac 0.3% Oph Susp (reference)
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- Actavis Inc.
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Inflammation, Pain
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02235272
- Testing
- XG-102
- Where
- United States
- Volunteers
- 339 people
- Sponsor
- Xigen SA
Blepharitis
Ocular Comfort and Inflammation in Lid Hygiene Therapy
The primary study objectives are: to evaluate (1) the change in ocular discomfort at 30 days and (2) the change in signs and symptoms of ocular surface disease in demodex-positive subjects beginning the use of Avenova.
- Trial name
- NCT02938078
- Testing
- Avenova Lid Cleanser
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Minnesota Eye Consultants, P.A.
Posterior Blepharoconjunctivitis
A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)
One objective of this study is to determine the levels of markers of inflammation on the eyelid margin of subjects with blepharoconjunctivitis and compare them with those of healthy volunteers.
- Trial name
- NCT01220258
- Testing
- Azithromycin ophthalmic solution, 1%
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ocular Inflammation, Keratoconjunctivitis
Tolerability Comparison of Flarex to Lotemax SM
This study compared the ocular tolerability of fluorometholone acetate ophthalmic suspension 0.1% (FLAREX) to loteprednol etabonate ophthalmic gel 0.38% (Lotemax SM) in adult subjects.
- Conditions
- Ocular Inflammation, Keratoconjunctivitis, Dry Eye Disease (DED), Post-operative Complications
- Trial name
- NCT07588074
- Testing
- Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38%
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Harrow Inc
Ocular Inflammation Associated With Blepharaconjunctivitis
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection…
- Trial name
- NCT00576251
- Testing
- Tobramycin 0.3%/Dexamethasone 0.05%, TOBRADEX
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Alcon Research